Clinical Trial

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-08-27; most recent amendment 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2021-02-07
Trial Details
NCT Number NCT04532606
Lead Sponsor Peking University First Hospital
Collaborators: Beijing Tsinghua Chang Gung Hospital, Navy General Hospital, Beijing, Guizhou Provincial People's Hospital, Jiangsu Provincial People's Hospital, Shanghai 10th People's Hospital
Conditions Benzodiazepines, Bladder Cancer, Delirium, Surgery, Cancer Recurrence
Enrollment 1,128 participants
Start Date 2021-02-05
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-30